{"name":"Ma Fei，MD","slug":"ma-fei-md","ticker":"","exchange":"","domain":"","description":"Ma Fei, MD is a specialized pharmaceutical company focused on the development and commercialization of oncology treatments. The company has a strong pipeline with two drugs in phase 3 trials, both formulations of eribulin, which target various types of cancer.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Eribulin biweekly regimen","genericName":"Eribulin biweekly regimen","slug":"eribulin-biweekly-regimen","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Eribulin standard regimen","genericName":"Eribulin standard regimen","slug":"eribulin-standard-regimen","indication":"Metastatic breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"Eribulin biweekly regimen","genericName":"Eribulin biweekly regimen","slug":"eribulin-biweekly-regimen","phase":"phase_3","mechanism":"Eribulin is a microtubule dynamics inhibitor that binds to tubulin and disrupts microtubule formation, leading to cancer cell death.","indications":["Metastatic breast cancer","Liposarcoma","Other advanced solid tumors (in clinical development)"],"catalyst":""},{"name":"Eribulin standard regimen","genericName":"Eribulin standard regimen","slug":"eribulin-standard-regimen","phase":"phase_3","mechanism":"Eribulin is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Liposarcoma","Other solid tumors (in clinical development)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}